DBV Presents Data Supporting Viaskin - Quick Facts

(RTTNews) - DBV Technologies (DBVT), a clinical-stage specialty biopharmaceutical company, said that further clinical and preclinical data supporting the use DBV's proprietary technology, Viaskin for EPIT, in the potential treatment of food allergies were presented at the 2015 Annual Meeting of the American Academy of Allergy, Asthma & Immunology in Houston, Texas, February 20-24.

DBV's data presentations included three oral presentations and three poster sessions, highlighting EPIT's role in the treatment of food allergies.

During a separate analyst and investor briefing, DBV will also provide a strategic update delineating development milestones for Viaskin in food allergies, allergic diseases, immunology, and vaccines.